Siemens Healthineers ELF Test Is Top Performer in Clinical Study
Siemens Healthineer’s ELF Test performed the best of the five blood biomarkers selected for the FNIH NIMBLE Study.
Read MorePosted by Chris Wolski | Nov 24, 2021 | Diabetes & Metabolic Diseases |
Siemens Healthineer’s ELF Test performed the best of the five blood biomarkers selected for the FNIH NIMBLE Study.
Read MorePosted by Chris Wolski | Oct 22, 2021 | Diabetes & Metabolic Diseases |
New research creates a road map for future treatments of nonalcoholic fatty liver disease and confirms the need for more mainstream screening.
Read MorePosted by Chris Wolski | Aug 30, 2021 | Diabetes & Metabolic Diseases |
Testing for, monitoring, and controlling diabetes continues to become more robust, cost-effective, and nuanced.
Read MorePosted by Chris Wolski | Aug 24, 2021 | Unknown Origin & Other Cancer Types |
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read MorePosted by Chris Wolski | Jun 17, 2021 | Diabetes & Metabolic Diseases |
Researchers have identified a noninvasive biomarker that can identify patients at risk of NAFLD complications using a simple blood test.
Read More